NDAINHALATIONLIQUID
Approved
Sep 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
3/8 — Basic
SUPRANE (desflurane) by Baxter is 12. First approved in 1992.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUPRANE (desflurane) is a volatile liquid general anesthetic administered via inhalation for induction and maintenance of anesthesia. It works by rapidly modulating CNS activity to produce unconsciousness, with clinical effects that closely track inspired concentration changes. Desflurane is used across outpatient and inpatient surgical procedures, with notably rapid emergence and recovery profiles compared to other volatile anesthetics.
LOE Approaching
Product is in late-stage lifecycle with limited growth potential; commercial teams are likely focused on margin management and transition planning rather than expansion initiatives.
Mechanism of Action
12.2 Pharmacodynamics Changes in the clinical effects of desflurane rapidly follow changes in the inspired concentration. The duration of anesthesia and selected recovery measures for desflurane are given in the following tables: In 178 female outpatients undergoing laparoscopy, premedicated with…
Worked on SUPRANE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.